Covid-19: Canada reports second case of blood clot caused by AZ jab; recovering patient

A second case has emerged in a person in Canada suffering from blood clots after taking AstraZeneca’s Covid-19 vaccine. However, Canadian health officials continued to recommend the vaccine to people over 55 years of age.

The case was reported Saturday in the province of Alberta in an unidentified man in his 60s. he had recently received a dose of the AZ vaccine manufactured by the Serum Institute of India (SII) in Pune under the brand name Covishield.

The man was “diagnosed, treated quickly and is recovering now,” tweeted Deena Hinshaw, Alberta’s chief medical officer of health.

Canadian health officials continue to urge people to get vaccinated and have defended the use of the AstraZeneca vaccine.

During a media interaction following the news of the case, Hinshaw said, “I continue to recommend AstraZeneca to anyone 55 years of age and over and recommend that all Albertans get vaccinated as soon as they get their flu shot. can. ”

She said this was only the second case in the country after the administration of more than 700,000 doses of the AstraZeneca vaccine.

The “overall rate” of these clots “has been estimated to be one case per 100,000 to 250,000 doses,” she said, adding that, on the other hand, “people aged 55 and over who contract the Covid-19 have a one in 200 chance of dying. And is also “at least 1,500 times more likely to be hospitalized due to Covid-19 than to suffer from this disorder” because of the vaccine.

The case has been confirmed by Health Canada. The agency tweeted: “Based on all the evidence available to date internationally, Health Canada continues to view the benefits of #AstraZeneca and Covishield vaccines in protesting Covid-19 outweighing the risks potentials. “

He said he continues to monitor these adverse actions. “The report of this case shows that the Canadian vaccine safety surveillance system is working,” he noted.

Hinshaw explained that, with health authorities aware of this reaction, they could “monitor it and further reduce the risk of serious injury or death.”

The first case in Canada of this particular Covishield reaction was reported on April 14 in a patient, a woman based in Quebec, who is also believed to be recovering.

Canada received 500,000 doses of Covishield on March 3 and the entire shipment was distributed nationwide.